About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

How Treatment of Parkinsonís Disease Gets Affected by Gut Bacteria?

by Mohamed Fathima S on January 19, 2019 at 2:58 PM
Font : A-A+

How Treatment of Parkinsonís Disease Gets Affected by Gut Bacteria?

Gut bacteria interrupt in the treatment of Parkinson's disease and make the medication less effective, reveals a study published in Nature Communications. A drug called levodopa which is used to treat the disease is converted to dopamine by the gut bacteria. The dopamine, a neurotransmitter cannot cross the blood-brain barrier, thereby reducing the effectiveness of treatment.

'It is well established that gut bacteria can affect the brain', explains Assistant Professor in Microbiology Sahar El Aidy, lead investigator of the study. 'There is a continuous chemical dialogue between gut bacteria and the brain, the so-called gut-brain axis.' El Aidy and her team investigated the ability of gut microbiota to influence the bioavailability of levodopa, a drug used in the treatment of Parkinson's disease.

Advertisement


Blood-brain barrier

The drug is usually taken orally, and the levodopa is absorbed in the small intestine and then transported through the bloodstream to the brain. However, decarboxylase enzymes can convert levodopa into dopamine. In contrast to levodopa, dopamine cannot cross the blood-brain barrier, so patients are also given a decarboxylase inhibitor. 'But the levels of levodopa that will reach the brain vary strongly among Parkinson's disease patients, and we questioned whether gut microbiota were playing a role in this difference', says El Aidy.
Advertisement

In bacterial samples from the small intestines of rats, Aidy's Ph.D. student Sebastiaan van Kessel found activity of the bacterial tyrosine decarboxylase enzyme, which normally converts tyrosine into tyramine, but was found to also convert levodopa into dopamine. 'We then determined that the source of this decarboxylase was Enterococcus bacteria.' The researchers also showed that the conversion of levodopa was not inhibited by a high concentration of the amino acid tyrosine, the main substrate of the bacterial tyrosine decarboxylase enzyme.

Bioavailability

As Parkinson's patients are given a decarboxylase inhibitor, the next step was to test the effect of several human decarboxylase inhibitors on the bacterial enzyme. 'It turned out that, for example, the inhibitor Carbidopa is over 10,000 times more potent in inhibiting the human decarboxylase', says El Aidy.

These findings led the team to the hypothesis that the presence of bacterial tyrosine decarboxylase would reduce the bioavailability of levodopa in Parkinson's patients. To confirm this, they tested stool samples from patients who were on a normal or high dose of levodopa. The relative abundance of the bacterial gene encoding for tyrosine decarboxylase correlated with the need for a higher dose of the drug. 'As these were stool samples, and the levodopa is absorbed in the small intestine, this was not yet solid proof. However, we confirmed our observation by showing that the higher abundance of bacterial enzyme in the small intestines of rats reduced levels of levodopa in the bloodstream', explains El Aidy.

Vicious circle

Another important finding in the study is the positive correlation between disease duration and levels of bacterial tyrosine decarboxylase. Some Parkinson's disease patients develop an overgrowth of small intestinal bacteria including Enterococci due to frequent uptake of proton pump inhibitors, which they use to treat gastrointestinal symptoms associated with the disease. Altogether, these factors result in a vicious circle leading to an increased levodopa/decarboxylase inhibitor dosage requirement in a subset of patients.

El Aidy concludes that the presence of the bacterial tyrosine decarboxylase enzyme can explain why some patients need more frequent dosages of levodopa to treat their motor fluctuations. 'This is considered to be a problem for Parkinson's disease patients, because a higher dose will result in dyskinesia, one of the major side effects of levodopa treatment.'



Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Senior Health News

Being Social can Make Older People Live Longer: Here's How
Happy long life to you: Being more social can increase the life span of older people. So, start socializing to add more years to your life.
 Late-Life Depression and Memory Loss Linked to Shorter DNA Sequences
The sequences of DNA at the extremity of chromosomes called telomeres seem to be a hallmark of depression and cognitive complaints in older adults.
Fracture Risk Lower Among Older Wheelchair Users
A new study has found that being a frail elderly person and using a wheelchair involves a substantially decreased risk of fractures.
 Making Old Blood Young Again Slows Down Aging
Could We Slow Aging by Rejuvenating Old Blood Stem Cells? Drugs used for arthritis may overturn aging effects on the blood system in mice.
Living Near a 'Food Swamp' may Up Stroke Risk in Older People
Is living near a food swamp bad for health? Yes, living near dense fast food and unhealthy food environments can put people over 50's at a higher risk of stroke.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

How Treatment of Parkinsonís Disease Gets Affected by Gut Bacteria? Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests